NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...

After years of construction and millions of dollars, the long-awaited CV Link is officially open — a 40-mile path stretching ...

Semaglutide therapy was associated with higher likelihood of passing low-risk cardiovascular thresholds among patients with ...

With such a large reduction, coupled with general skepticism around PUFAs, experts would like to see the trial replicated.

Oral semaglutide 25 mg was associated with improved glycemic parameters and cardiovascular risk across weight loss categories ...

Tata Motors (CV) shares fell, extending last week’s slide, after its first post-listing quarterly results showed a sharp ...

Following the approvals from exchanges, Tata Motors had informed in an exchange filing this week that its CV business will ...

The new entity, Tata Motors Ltd (CV), will be India’s largest commercial vehicle manufacturer, with a wide portfolio spanning ...